Sophiris Bio Inc. is a clinical-stage biopharmaceutical company focused on developing products for the treatment of urological diseases. The Company is involved in the development of PRX302, which is used for treatment of the symptoms of benign prostatic hyperplasia and referred to as an enlarged prostate. PRX302 is a genetically modified recombinant protein that is delivered through ultrasound-guided injection directly into the prostate. It is delivered through a targeted injection into the prostate, ablating the prostate tissue without damaging neighboring tissue and nerves. This method of administration limits the circulation of the drug in the body. The Company holds commercial rights of PRX302 in markets, including, Canada, the United States, Europe and Asia (except Japan).